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Abstract
Background: Several cases of myopathies have been observed in the horse Norman Cob breed.
Muscle histology examinations revealed that some families suffer from a polysaccharide storage
myopathy (PSSM). It is assumed that a gene expression signature related to PSSM should be
observed at the transcriptional level because the glycogen storage disease could also be linked to
other dysfunctions in gene regulation. Thus, the functional genomic approach could be conducted
in order to provide new knowledge about the metabolic disorders related to PSSM. We propose
exploring the PSSM muscle fiber metabolic disorders by measuring gene expression in relationship
with the histological phenotype.
Results: Genotypying analysis of GYS1 mutation revealed 2 homozygous (AA) and 5 heterozygous
(GA) PSSM horses. In the PSSM muscles, histological data revealed PAS positive amylase resistant
abnormal polysaccharides, inflammation, necrosis, and lipomatosis and active regeneration of fibers.
Ultrastructural evaluation revealed a decrease of mitochondrial number and structural disorders.
Extensive accumulation of an abnormal polysaccharide displaced and partially replaced
mitochondria and myofibrils. The severity of the disease was higher in the two homozygous PSSM
horses.
Gene expression analysis revealed 129 genes significantly modulated (p < 0.05). The following genes
were up-regulated over 2 fold: IL18, CTSS, LUM, CD44, FN1, GST01. The most down-regulated
genes were the following: mitochondrial tRNA, SLC2A2, PRKCα, VEGFα. Data mining analysis
showed that protein synthesis, apoptosis, cellular movement, growth and proliferation were the
main cellular functions significantly associated with the modulated genes (p < 0.05). Several up-
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BMC Veterinary Research 2009, 5:29 http://www.biomedcentral.com/1746-6148/5/29regulated genes, especially IL18, revealed a severe muscular inflammation in PSSM muscles. The up-
regulation of glycogen synthase kinase-3 (GSK3β) under its active form could be responsible for
glycogen synthase (GYS1) inhibition and hypoxia-inducible factor (HIF1α) destabilization.
Conclusion: The main disorders observed in PSSM muscles could be related to mitochondrial
dysfunctions, glycogenesis inhibition and the chronic hypoxia of the PSSM muscles.
Background
Several cases of metabolic myopathies have been
observed in the Norman Cob horse breed used to pull car-
riages [1]. Muscle histology examinations revealed that
one bloodline suffers from a glycogenosis described as
polysaccharide storage myopathy (PSSM) in Quarter
horses [2,3] and classified as non-exertional myopathies
with rhadomyolysis in equine muscle disorders [4]. The
disease has also been observed in Andalusian horses
(Spanish purebred horses) [5], Belgian Draft Horses, Mor-
gan, Arabian, Standardbred, ponies, Warm-blooded
horses [6] and a mule [7]. The prevalence of PSSM among
overtly healthy Quarter Horses in the United States is
likely to be between 6% and 12% [8]. A PSSM phenotype
has been characterized in a Norman Cob horse pedigree
and in a population of stallions, by histological demon-
stration in striated muscular fibers of an accumulation of
some periodic acid Schiff (PAS)-positive amylase-resistant
polysaccharides appearing ultrastructurally as glycogen-
like particles [1,9]. Using this criteria, the affection preva-
lence was 33% among a sample of French stallions. The
prevalence of PSSM in Norman Cob stallions was closer to
the 36% PSSM affected horses diagnosed in Belgian Draft
Horses [10] than the 8% observed in draft horses in the
United Kingdom [11]. The common clinical signs of
PSSM in various breeds are abnormal hind limb gait, poor
muscling, generalized muscle atrophy, poor performance,
back soreness, exercise intolerance, spontaneous decum-
bency with inability to rise, episodic "colic" and rhab-
domyolysis [12].
In Humans, 11 types of glycogenosis (or glycogen storage
diseases) have been described, each containing several
sub-types [13]. The genes responsible for glycogen storage
diseases in humans [13] or involved in the glycogen path-
way were identified in the PubMed data basis and could
be considered as candidates for equine PSSM: G6PC,
SLC37A4, NPT4, GAA, AGL, GBE1, GBE2, PYGM, PYGL,
PFKM, PHKA2, PHKB, PHKG2, PHKA1, PHKG1, GYS1,
GYS2. However, in equine PSSM, the aetiology and phys-
iopathology are not known. The excessive glycogen stor-
age and formation of abnormal polysaccharide in PSSM
horses therefore appears to reflect an increase in glycogen
synthesis rather than a decrease in its utilisation [3]. Glu-
cose tolerance tests showed that PSSM horses have
enhanced cellular uptake of glucose and an increased sen-
sitivity to insulin [14]. Neither glycogenolytic or glycolytic
enzyme deficiencies, nor abnormality in the phosphofruc-
tokinase (PFKM) regulation, have been identified in
affected horses [2,15]. The enhanced insulin sensitivity in
PSSM horses is not due to an increase of the glucose trans-
porter GLUT4 content or insulin receptor quantity [16].
Attempts to measure branching enzyme activities with
methods developed for human muscle were unsuccessful
[2]. Linkage studies did not demonstrate the relationships
between PSSM and the candidate genes AMPK [17,18] or
AGL [19]. A specific form of fatal glycogen storage disease
was observed in a Quarter horse foal where a nonsense
mutation in codon 34 of the glycogen branching enzyme
(GBE1) was identified [20]. This metabolic myopathy can
be compared to human glycogenosis type IV where several
mutations and deletions explain the total or partial defi-
ciency of the GBE1 gene. In adult horses, a new G-to-A
mutation within the gene encoding glycogen synthase 1
(GYS1) has recently been observed in Quarter horses and
some warm-blooded horses [21]. It is assumed that the
metabolic disorders of PSSM muscles could be observed
in detail at the transcription level because the gene(s)
responsible for glycogen storage disease would also be
linked to other dysfunctions and to some failure in gene
regulatory networks. Thus, the functional genomics
approach could be conducted in order to provide new
knowledge about the metabolic disorders related to
PSSM. For a better understanding of the PSSM physiopa-
thology in Norman Cob horses, we propose exploring the
PSSM muscle fiber metabolic disorders by measuring gene
expression in relationship with the histological pheno-
type.
Methods
Horses, genotyping and muscle biopsies
All the horses were genotyped for the GYS1 c.926G>A
mutation [21] (wild type GG, heterozygous GA or
homozygous AA).
A biopsy of the gluteus medius muscle was performed in 13
Norman adult horses: 4 females and 9 males, 4–17 years
old. This muscle was chosen because of (i) its important
propulsion function in horse locomotion, (ii) its early
and major histological involvement in the course of the
disease [1] and (iii) the good standardization of biopsy
sampling [22]. The horses were sedated and received a
local anaesthesia before making a small skin incision
according to a standardized protocol used in routine forPage 2 of 22
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partment of the gluteus medius was performed at the first
third distance between the sacral and coxae tuber. A biopsy
needle with automatic sampling was vertically inserted
until its extremity just under the fascia corresponding to a
3.5 cm depth for the gluteus medius. Each muscle biopsy
was divided in two parts, and the first part was frozen in
isopentane cooled with liquid nitrogen for histological
analysis and the second part was collected for genomic
analysis. The blood was removed by absorbing it with a
compress and immediately frozen in the RNA later® at -
80°C. Informed consent was obtained from the horse
owner, the French National Studs (Les Haras Nationaux),
and the study was approved by the animal care committee
of the National Research Institute of Agriculture (INRA).
Histological analysis
Briefly, the muscle samples were serially sectioned (8 mm
thick) and each section was stained with either hematox-
ylin-eosin-safranine (HES), or periodic acid-Schiff (PAS)
with or without incubation for 20 minutes at 37°C with
α-amylase [1]. Intracytoplasmic presence of amylase-
resistant material was used as diagnosis criteria for PSSM:
seven were PSSM horses and six were control horses [2].
Morphometric analysis was performed additionally for
histologic quantitative evaluation using a digital camera
(Nikon DXM 1200, Badhoevedo, Netherlands) combined
with image-analyzing software (Lucia imaging software,
Laboratory Imaging Inc., Prague, Czech Republic). Per-
centages of aggregate-containing and vacuolated fibers
were calculated as described previously [1] from each PAS-
amylase-stained and HES-stained sections respectively.
Additional biopsies from one PSSM horse (#49) was des-
ignated for routine electron microscopy and subsequently
fixed in 2.5% buffered glutaraldehyde, postfixed in
osmium tetroxide, embedded in epoxy resin, cut into 1-
mm-thick sections, stained with uranyl acetate and lead
citrate, and examined by transmission electron micros-
copy.
Production of the equine long oligonucleotide microarray
Gene expression analysis was performed using a home-
made equine long oligonucleotide microarray which
included 384 equine transcripts: 50 probes of the mito-
chondrial genome and 334 probes of the nuclear genome
[see Additional file 1 and GEO Platform accession
number GPL8349: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GPL8349]. This equine oligonucleotide
microarray was designed according to the derived method
used for open access human and mouse long oligonucle-
otide microarrays [23]. Briefly, the list of human anno-
tated genes (available in the NCBI public data base)
involved in muscle structure, contraction, energetic
metabolism and inflammation processes was used to
identify the equine candidate genes that could be interest-
ing to put on the microarray. Then, this list of candidates
was crossed with the orthologous equine sequences avail-
able in 2006 on the NCBI data base using a blast method
[24]. In addition, 50 other probes of the equine mito-
chondrial genome were designed to measure the expres-
sion of the 13 genes (2 different probes per protein gene)
coding for the protein units of the respiratory chain as
well as 22 tRNA and 2 rRNA. Finally, 384 probes of 50
nucleotides long were calculated and synthesized with a 5'
terminal – NH2 modification in order to attach the probe
on the slides. The microarrays were spotted at the micro-
array service (LEFG, CEA, Evry, France) by printing the
equine probes, suspended in a spotting buffer composed
of 50% dimethyl sulfoxide (DMSO) and TE on hydrogel
slides (Schott Nexterion), with a Microgrid-II-robot. The
equine microarray can be spotted alone on a slide or
jointly with the 25 K mouse oligonucleotide microarray
[23].
This equine microarray has been validated by a reproduc-
ibility test, competition test, biological test for equine
transcript analysis extracted from different muscles of dif-
ferent equine breeds and health status [unpublished
data]. Fourteen microarrays were used for analysis of each
PSSM muscle sample against reference control muscles
using two fluorochromes in a dye-swap design (duplicate
measurements).
RNA extraction
Total RNA was extracted from tissues by a phenol-chloro-
form method (TRIZOL® reagent). The quality of total RNA
was verified by micro channel electrophoresis (RNA 6000
Nano LabChip®, Bioanalyzer®). The total RNA concentra-
tion and RNA purity were measured by optical density
with a spectrophotometer at 260 nm and the ratio 260/
280 (Nanodrop®). RNA was considered as pure when the
260 nm out of 280 nm absorbance ratio was close to 2.
The RNA were stored at -80°C.
RNA in vitro transcription
The synthesis of RNA with a polyA tail was performed
using in vitro transcription with aminoallyl UTP. A total
RNA (1 μg) was used to start the synthesis using the in
vitro transcription kit according to the manufacturer's
protocol (Aminoallyl MessageAmp® II aRNA). This
method equally increased the number of mRNA copies of
each transcript without changing the proportion of the
initial population of transcripts. The integrity and concen-
tration of aminoallyl RNA (aaRNA) were checked again by
micro channel electrophoresis (RNA 6000 Nano
LabChip®, Bioanalyzer®) and a spectrophotometer (Nono-
drop®). The aaRNA were stored at -80°C.Page 3 of 22
(page number not for citation purposes)
BMC Veterinary Research 2009, 5:29 http://www.biomedcentral.com/1746-6148/5/29Microrray hybridization and signal quantification
All the samples of PSSM muscles were hybridized against
the reference control muscles. This reference was made by
pooling together all the mRNA extracted after in vitro
transcription from the 6 control muscles of the sound
horses. Briefly, the hybridization protocol [24] included
the following steps. After purification of the amino-mod-
ified RNA, monofunctional forms of the Cyanine 3 (Cy3)
or Cyanine 5 (Cy5) fluorochrome were coupled to 5 μg of
the studied sample and control sample by an indirect
method: the ester groups linked to the fluorochromes
were bound on the amino-allyl groups incorporated on
the RNA during the in vitro transcription. The marked tar-
gets were then mixed and hybridized on the same chip for
immediate comparison of the two nucleic acid popula-
tions. For each sample, a dye-swap (duplicate measure-
ment) was performed to avoid asymmetry of marker
affinity (Cy3 and Cy5). The two results were averaged
before statistical results.
The 5 μg of aaRNA were completely vacuum-dried and
resuspended in 9 μL of coupling buffer and 11 μL of dye,
the tubes were mixed by vortexing and incubated for 30
minutes in the dark. The reaction was quenched by addi-
tion of 0.73 M Hydroxylamine and incubation for 15
minutes in the dark. Excess dye was removed from the
labeled aaRNA by purification on a column. Purified
labeled aaRNA were subsequently mixed with 10 μg poly
(A) RNA, 10 μg yeast tRNA, 10 μg Cot 1 mouse RNA, then
precipitated with 0.5 volumes of 7.5 M ammonium ace-
tate and 2.5 volumes of absolute ethanol. After centrifuga-
tion at 16,000 × g for 45 minutes to 1 hour at 4°C, the
supernatant was removed and the pellet was washed once
with 700 μL of 70% ethanol. The samples were centri-
fuged at 16000 g for 15 minutes at 4°C. The aaRNA pellet
was vacuum-dried for 1 minute and then dissolved in 50
μL of the hybridization mix preheated at 50°C: 2 × SSC,
0.1% SDS and 0.1% Salmon sperm DNA. It was mixed by
vortexing and incubated in a water bath at 50°C to dis-
solve the mRNA pellet. Each slide was rehydrated in a
humidified chamber for 1 hour at room temperature then
dried in a dessicator for 1 hour. The slides were prehybrid-
ized in 0.3% Ethanolamine and 0.05 M Na Borate pH9.
The slides were plunged 1 minute in water and dried by
centrifugation for 7 minutes at 100 × g. The probe was
heated for 2 minutes at 100°C and placed between the
slide and a cover slip. The arrays were incubated overnight
in a water bath at 50°C in a humidified slide chamber and
washed in a first solution of 0.1 × SSC with 0.1% SDS for
5 minutes followed by two washing steps in 0.1× SSC for
5 minutes each at room temperature, under agitation and
safe from the light. The arrays were dried by centrifugation
at 100 × g for 7 minutes. The image of fluorescence inten-
sities of Cy3 (532 nm) and Cy5 (635 nm) were scanned
separately with the laser scanner (GenePix® 4000B).
The tiff images (10 μm/pixel) were analyzed using a spe-
cific software for microarray image analysis (GenePix® Pro
6.0 software) which allowed locating the spots automati-
cally with manual control and quantifying the fluores-
cence intensity of each spot. For each microarray, the data
output were the fluorescence intensities of all the spots
corresponding to each gene. These data were imported in
a genomic data analysis software (Gene Spring® software)
to normalize the data before filtering and statistical anal-
ysis. For each sample (horse), a duplicate analysis (dye-
swap) was made and the average fluorescence results were
used. Then, all the results were normalized per spot and
per microarray by the Lowess regression method in order
to remove systematic variations. Finally, for each sample
and each gene an expression ratio was obtained:
Ratio = Expression of each PSSM muscle/expression in
the reference control muscle
For statistical analysis, a log transformation ratio was used
to normalize the distribution. A list of the significant
genes were obtained by filtering the genes with a cut-off t-
test p-value p < 0.05 with Benjamini and Hochberg mul-
tiple testing correction method to avoid a false discovery
rate [25]. The Student t-test detected the mean expression
ratio of replicates which are significantly different from
one (expression ratio = 1, means no gene expression
change).
Real time quantitative RT-PCR
In order to validate the equine microarray results, quanti-
tative RT-PCR were conducted in triplicate for the top ten
up and down-regulated gene transcripts both in control
and PSSM horses. The primers were designed using Primer
express software (Applied Biosystem) (Table 1). All the
reactions were carried out on the real time PCR system
7500 (Applied Biosystems). Briefly, reverse transcription
was performed on 20 ng of aaRNA obtained by aminoallyl
amplification (RNA used for microarray hybidization and
RT-PCR were issued from the same preparation). Random
primers (100 ng) and 10 pmol of dATP, dCTP, dGTP and
dTTP were added to RNA in a 13 μL final volume. The
reaction tubes were incubated at 70°C for 5 min. The ran-
dom annealing primer was performed by an incubation at
room temperature (~25°C) for 10 min. Four microliters
of 5× first strand buffer, 200 pmol of DTT and 200 U of
Superscript II reverse transcriptase were added in the tube
for a 20 μL final volume and incubated at 42°C for 1
hour. The enzyme was inactivated by incubating the mix-
ture at 70°C for 15 min. The cDNA concentration was
measured by optical density with a spectrometer that
measured absorbance at 260 and 280 nm (Nanodrop®).
The equine cDNA solution was diluted in water to obtain
a final concentration of 20 ng/μL and stored at -20°C.
Complementary DNA (100 ng) obtained from aaRNA wasPage 4 of 22
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Gene Primer name Primer sequence Length Salt Tm GC%
IL18 IL18_1Fwd TGCATTAGCTTGGTGGAAATG 21 61 42
IL18_1Rev AGGTTCAAGCCTGCCAAAGT 20 61 50
CTSS CTSS_1Fwd ACAACGGCATCGATTCAGAC 20 61 50
CTSS_1Rev GCCAAAGGGAAGTTCGGTAT 20 60 50
LUM LUM_1Fwd CCTGGAGGTCAATGAACTTGAA 22 61 45
LUM_1Rev ACGCAAATGCTTGATCTTGG 20 61 45
CD44 CD44_1Fwd GATCCACCCCAACTCCATCT 20 61 55
CD44_1Rev TGACCGAGGTGCAGTCTTCT 20 61 55
FN1 FN1_1Fwd CCCTGGTGTCACAGAGGCTA 20 61 60
FN1_1Rev AGTTGGGGAGGCTCATCTGT 20 61 55
GSTO1 GSTO1_1Fwd TACCTCATCTGGCCCTGGTT 20 62 55
GSTO1_1Rev ATGGCTTCCATCCAGAGCTT 20 61 55
VCAM1 VCAM1_1Fwd GCACTGCCATTGAGATGTGA 20 61 50
VCAM1_1Rev TGCAATGTTGCTATGGCTCA 20 61 45
ITGB1 ITGB1_1Fwd TCTCCAGAAGGTGGCTTTGA 20 61 50
ITGB1_1Rev TCCGTGGAAAATACCAGCAG 20 61 50
CXCR4 CXCR4_1Fwd GCAGCAGCAGGTAGCAAAGT 20 61 55
CXCR4_1Rev CCACGTCATCCTCCGTGTAG 20 61 60
HIF1A HIF1A_1Fwd GGACTCGGATCATCTGACCA 20 61 55
HIF1A_1Rev TATCCCCCTCTTTTGGCAAG 20 61 50
NFKBIB NFKBIB_1Fwd CGTCATCCACAAAGATGCAG 20 60 50
NFKBIB_1Rev CTGGGCCTCAACAGCCTAGT 20 62 60
PLCG2 PLCG2_1Fwd CATCTTGTACGGCACCCAGT 20 61 55
PLCG2_1Rev TTCAAGCCAGACAGCCACTT 20 61 50
ND3 ND3fwd CCACAACTAAACATCTATGCAGAAAAA 27 62 33
ND3rev GGAGGCGTGCTGACCCTAT 19 62 63
SLC25a17 SLC25a17_1Fwd GCAATCTGGGTCAAAGGTCA 20 61 50
SLC25a17_1Rev GCCCCTTGCAGCTTTAGTCT 20 61 55Page 5 of 22
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specific primer and 10 μL SYBR® Green PCR Master Mix.
Amplification steps were as follows: 10 min denaturation
at 95°C, 40 cycles of denaturation at 95°C for 15 s and
annealing extension at 60°C for 1 min. The comparative
threshold cycle (CT) method was used for the calculation
of amplification as specified by the manufacturer. The
expression results of the quantitative RT-PCR of the con-
trol and PSSM horses were normalized by the mean CT of
the reference gene 12S rRNA measured in all the muscle
samples and the relative expression ratio of PSSM against
the control group was calculated.
Data mining
A biological interpretation of the data was performed
using two types of analysis to identify the main biological
functions and the main metabolic pathway disorders
revealed by the expression profile of the PSSM muscles.
The categorization of the gene functions was generated
through the use of Ingenuity® Pathway Analysis http://
www.ingenuity.com. The analysis identified the biologi-
cal functions that were the most significant to the gene list
results. The significant genes associated with biological
functions in the knowledge database (gene functions
described in published papers) were considered for the
analysis. The Fischer exact test was used to calculate a p-
value determining the probability that each biological
function assigned to that data set is due to chance alone.
The analysis of the main metabolic pathways and their
dysfunctions was performed using a Java/Perl software,
Predictsearch® (Prediguard, http://prediguard.com/pre
dictsearch.htm) which has been previously described in
[26]. This software allows the characterization of the path-
ways as well as the functional networks in which the
selected genes were involved. Briefly, gene aliases corre-
sponding to the significant modulated genes were submit-
ted as queries to PubMed in order to collect titles and
abstracts of all related publications. The results are pre-
sented in a 2D graph that shows the relationships between
each gene and cell type, cellular compartment, and bio-
logical function.
Results
Genotypes and histological phenotypes
The PSSM horse genotypes for the GYS1 c.926G>A muta-
tion were 5 heterozygous (AG) and 2 homozygous (AA)
(Table 2). The 6 control horses were wild type (GG). Het-
erozygosity seemed to be consistent with the dominant
mode of inheritance.
SRI SRI_1Fwd ATTGCCGGAGGATACAAACC 20 61 50
SRI_1Rev GCCATTCAGTACAGCCCAGA 20 61 55
ND5 ND5fwd GATGATGATACGGCCGAACAG 21 61 52
ND5rev CCCGATGCGGTTATAAAGGA 20 58 50
PDE4D PDE4D_1Fwd AGCCTGCGAACTGTACGAAA 20 61 50
PDE4D_1Rev ATGGATGGTTGGTTGCACAT 20 61 45
SLC25a15 SLC25a15_1Fwd TGAACTGAGCCGATCGTTTT 20 61 45
SLC25a15_1Rev CAGAGGCAGATTCCACCAAC 20 61 55
VEGF VEGF_1Fwd TCTACCTCCACCATGCCAAG 20 61 55
VEGF_1Rev GTCTCGATTGGACGGCAGTA 20 61 55
PRKCA PRKCA_1Fwd GACTTCATGGGCTCCCTTTC 20 61 55
PRKCA_1Rev TCTTCGTCCCCTTCTGGAAT 20 61 50
SLC2A2 SLC2A2_1Fwd GCCATCGGTACTCTTCACCA 20 61 55
SLC2A2_1Rev TGTGCCACAGCTTCTGATTG 20 61 50
Table 1: List of the primers used for real time quantitative RT-PCR. (Continued)Page 6 of 22
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used as diagnosis criteria for PSSM, was observed in biop-
sies of the 7 out of the 13 horses (Figure 1). Two horses
were graded as mildly affected (less than 3% of fibers con-
taining PAS positive amylase resistant material) and five
horses as severely affected (10 to 20% of affected fibers)
(Table 2) using quantitative evaluation of aggregate-con-
taining fibers as previously published [1]. The two
homozygous horses were histologically severely affected.
Heterozygous horses could present the mild (n = 2) or the
severe (n = 3) phenotype.
Some other myopathic changes were also identified in
affected horses with marked individual variations.
Numerous fibers underwent segmental necrosis that was
associated with mononuclear cell infiltration foci (Figure
1). Some of these foci were centered on fragmented fibers
with many macrophages phagocytizing cellular necrotic
debris. Strikingly, fiber necrosis was more prominent in
homozygous PSSM horses. In this marked inflammatory
context, some endomysial fibrosis was also present. Addi-
tionally, in all PSSM muscles, we noted an increased
number of central nuclei. This change corresponds to
muscular regeneration. Some degree of anisocytosis of
muscular fibers was always present in affected muscles
and was more severe in the two homozygous horses. Fatty
infiltration of muscular fascia and replacement of muscle
fibers by adipose tissue was also sometimes observed, this
change being particularly severe in one homozygous
horse.
Ultrastructural evaluation of one severely affected horse
(#49) was performed (Figure 2). Extensive accumulation
of an abnormal polysaccharide appearing as dense parti-
cles, displaced and partially replaced mitochondria and
myofibrils, a number of which was severely decreased.
This accumulation was exclusively cytoplasmic, mem-
brane unbound and particularly abundant around nuclei
and in the subsarcolemmal region of the cytoplasm,
where numerous mitochondria are normally present in
sound animals. Strikingly, we also reported some mito-
chondrial ultrastructural changes, namely a decrease of
the cristae number, formation of myelinic bodies and
swelling.
Gene transcript expressions
Thirty-three percent of the probes of the micorarray were
significantly hybridized with a high fluorescence value,
Table 2: Genotype of GYS1 mutation and histological data of the horses.
Horse PSSM 
disease 
status
Genotype Histological 
grading
Age 
(years)
Sex Vacuolized 
fibers (%)
Inflammation Necrosis Central 
nuclei
Anisocytosis Lipomatosis Aggregate 
containing 
fibers (%)
10 0 GG 16 M ND 0
29 0 GG 15 M 0 0
35 0 GG 8 M 0 0
40 0 GG 8 M 0 0
56 0 GG 6 F 0 0
34 0 GG 10 M 0 0
38 PSSM GA 1 12 M 14.1 mild mild numerous mild none 2.5
54 PSSM GA 1 4 F 2.5 none none several minimal mild 2.4
12 PSSM GA 2 17 M 7.3 mild mild numerous mild mild 20.6
32 PSSM GA 2 6 M 1.4 mild none several mild none 17.0
42 PSSM GA 2 9 F ND minimal mild several mild mild 9.9
44 PSSM AA 2 17 F 21.9 mild severe several severe mild 10.5
49 PSSM AA 2 10 M 34.1 severe severe numerous severe severe 18.9
Genotypes: GG = wild type, GA = heterozygous, AA = homozygousPage 7 of 22
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present study have been deposited in NCBI's Gene Expres-
sion Omnibus and are accessible through GEO series acces-
sion number GSE15572 http://www.ncbi.nlm.nih.gov/
sites/entrez?db=gds&cmd=search&term=GSE15572.
After filtering the normalized expression ratios with a cut-
off at p < 0.05 (normalized ratio significantly different
from 1), a total of 129 genes exhibited significant changes
of expression levels between PSSM and control muscles
(Table 3). This set contained 16 up-regulated genes (nor-
malized ratio > 1.5), 37 down-regulated genes (normal-
ized ratio < 0.66) and 76 moderately modulated genes
(0.66 < normalized ratio < 0.9 and 1.07 < normalized
ratio < 1.5). This list of significant genes was used for the
rest of the study. The maximal up-regulation value was
observed for interleukin 18 (IL18) 6.2 fold change, and
the following genes were up-regulated up to 2 fold: CTSS,
LUM, CD44, FN1, GST01. The maximum down regula-
tion was observed for the mitochondrial tRNA genes
(TRNQ, TRNC, TRNN, TRNY, TRNA) from -4.83 to -2.86
fold changes. The three most down-regulated genes cod-
ing for proteins were the following: SLC2A2 or GLUT2 (-
2.84), PRKCα (-2.72), VEGFα (-2.68).
Ultrastructural evaluation of muscular biopsy from a PSSM affected Norman Cob horse #49Figure 2
Ultrastructural evaluation of muscular biopsy from a 
PSSM affected Norman Cob horse #49. (A) Transversal 
section. (B) Longitudinal section. Severe mitochondrial (m) 
and myofibrillar (f) loss due to abnormal accumulation of 
granular material (arrowhead) resembling glycogen. Some 
myelinic bodies (arrow) were present that demonstrated 
mitochondrial degeneration. A nucleus is indicated (n).
A
B
Histological evaluation of muscular biopsies from Norman Cob h rsesFigure 1
Histological evaluation of muscular biopsies from 
Norman Cob horses. (A) Severe form of polysaccharide 
storage myopathy corresponding to a homozygous horse (# 
44) for the GYS1 c.926 A allele. Numerous muscle fibers 
contained abnormal accumulation of polysaccharidic material 
(arrowheads). The endomysium was focally infiltrated by 
mononuclear cells (°), some adipocytes (*) and was diffusely 
thickened by fibrosis (arrows). (B) Mild form of polysaccha-
ride storage myopathy corresponding to a heterozygous 
horse (# 54) for the GYS1 c.926 A allele. Compared to the 
severe form of the disease, the number of polysaccharide 
containing fibers (arrowheads) was lower and the endomy-
sium was subnormal except for some fatty infiltration (°). (C) 
Muscle aspect of a control horse (#56). (A-C) Hematoxylin-
eosin-safranine staining.
A
B
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down-regulated between PSSM and the control group
were compared to the results obtained by microarray anal-
ysis (Table 4). A significant correlation of r = 0.54 (p <
0.01) between the two methods was calculated. As in
microarray results, the mitochondrial genes ND3 and
ND5 were found down-regulated using quantitative RT-
PCR analysis. The hypoxia markers were also in agree-
ment: VEGFα was down-regulated and HIF1α was up-reg-
ulated. All inflammation markers (IL18, CTSS, LUM,
CD44, GSTO1, VCAM1, ITGB1, CXCR4) were up-regu-
lated as in microarray results except FN1 and ITGB1 which
were found down-regulated. The gene markers of aerobic
pathway SLC25a17 was found up-regulated by quantita-
tive RT-PCR and SCL25a15 down-regulated as in microar-
ray data.
Gene functions and pathways
Our list of modulated genes was classified by categories of
cellular functions, canonical pathways and signaling path-
ways using Ingenuity Pathway Analysis®. Protein synthe-
sis, apoptosis, cellular movement, growth and
proliferation are the main significant cellular functions (p
< 0.05) that are associated to the modulated genes (Figure
3). The main significant (p < 0.05) canonical pathways
concerned oxidative phosphorylation, ubiquinone bio-
sythesis, aminosugar and purine metabolism. The main
significant signaling pathways (p < 0.05) were related to
G-protein couple receptor, hypoxia, NF-κB, VEGFα and
IL6, IL10, apoptosis and leukocyte extravasation signal-
ing. The main metabolic disorders significantly (p < 3.3
10-4) detected were mitochondrial dysfunction, hypoxia
and alteration of NF-κB activity.
The main tissue, organ and cellular context and the bio-
logical activities that were cited in relationship with the set
of genes were further investigated using Predictsearch®
analysis. Using the PubMed database, it was found that a
part of the significant modulated genes were strongly
associated with the following terms: skeletal muscle,
mitochondria, myoblast, endoplasmic reticulum. (Figure
4). In addition, the more frequent biological activities
cited in relationship with the set of genes were glycolysis,
respiratory chain, hypoxia, glycogen synthase, inflamma-
tory myopathy (Figure 5). The main metabolic pathway
disorders are described in the figures 6, 7 and 8 using
these data (see Additional file 2 for the legends of the
pathway drawings). In the mitochondria, all the genes
were down regulated (Figure 6). The tRNA were severely
down regulated (fold change between -4.83 and -2.27).
The other mitochondrial genes ND2, ND3, ND5, ND6,
COX2 and COX3 were moderately down regulated but
with low expression values (fold changes between -1.31
and -1.85). Other nuclear genes involved in the aerobic
metabolism of the mitochondria were down regulated as
well: UCP2, GNAS, SLC25a15, SLC2a2 (GLUT2), ATP5L,
ATP5J, ATP5D and ATP5H.
A chronic inflammation process of the muscle was
revealed by many up-regulated genes like interleukin 18
(IL18), CD44, CD69, CTSS, FN1, HSPA5, ITGB1, ITGB2,
VCAM, CXCR4 LTF, GSTO1 and LUM (Figure 7).
The up-regulation of the glycogen synthase kinase-3
(GSK3β) under its active form could be responsible for
glycogen synthase inhibition, and for hypoxic transcrip-
tion factor inhibition (HIF1α) by phosphorylation as
indicated by data mining analysis (Figure 8). In addition,
VEGFα was down-regulated and avoided capillarization
and oxygen distribution of the new regenerated muscle
fibers. These gene regulations increased muscle hypoxia.
Other interesting genes were slightly up-regulated: ENO1
(1.39) was involved in the end of glycolysis; IGF2 (1.34)
was involved in the growth hormone activity in muscle
differentiation; EPO (1.28) was involved in hematopoi-
etic function. Some other genes were slightly down-regu-
lated: PYGL (-1.11) was involved in glycogen metabolism;
IL6ST (-1.20), IL7 (-1.19) were involved in hematoprotein
signaling; MIF (-1.30) was involved in cell inflammatory
regulation. GSK3β, PYGL, GLUT2 are the only genes
closely related to glycogen metabolism.
Discussion
The equine genome has been recently sequenced and pub-
lished. However, there is no equine DNA microarray com-
mercially available to date. Three homemade cDNA
microarrays have been designed using transcripts
extracted from equine joint cartilage and synoviocytes
[27-29]. This first cDNA microarray was tissue specific and
poorly annotated. Another approach to analyse gene
expression in equine leukocytes and muscles was to use a
heterologous 15 K cDNA microarray designed from
murine embryonic tissues by the National Institute on
Aging [30]. It includes 15,264 unique genes for which
about 11,000 are annotated. It has been demonstrated by
several tests that mouse cDNA microarrays can adequately
hybridize equine genes expressed in muscles [31]. It was
assumed that interspecific hybridization between an
equine cDNA and a probe of 1,500 nucleotide length is
possible between two mammal species because the genes
involved in the basic cellular functions are highly con-
served during mammal evolution as observed for myosin
heavy chains [32]. The same mouse 15 K cDNA microar-
ray has been used to detect inflammation and oxidative
stress by the study of leukocyte gene expression in endur-
ance horses performing a race of 140 km [33]. In order to
improve specificity of the hybridization and to focus on a
few numbers of functions of the genes (inflammation,
muscle metabolism), an equine oligonucleotide microar-Page 9 of 22
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BMC Veterinary Research 2009, 5:29 http://www.biomedcentral.com/1746-6148/5/29Table 3: List of significant modulated genes (p < 0.05) expressed in the muscles suffering from PSSM.
Gene name EST – Sequence Entrez Gene Normalized ratio P-value < 0.05
IL18 Y11131 3606 6.20 1.58E-03
CTSS CD464451 1520 3.17 3.24E-03
LUM CX594607 4060 3.15 8.40E-04
CD44 CD464887 960 2.42 9.56E-04
FN1 ECU52108 2335 2.17 5.10E-03
GSTO1 CX603867 9446 2.03 2.64E-03
VCAM1 CX602484 7412 1.98 2.76E-02
ITGB1 CX598727 3688 1.87 2.31E-03
CXCR4 CD466324 7852 1.81 2.74E-02
HIF1A CX602270 3091 1.73 1.36E-03
ITGB2 CD535228 3689 1.70 4.26E-04
HSPA5 CX604607 3309 1.69 1.42E-02
GNAS BM734975 2778 1.63 1.45E-03
CD69 CD528606 969 1.62 2.67E-02
LTF ECA010930 4057 1.58 1.73E-02
GSK3B CX592808 2932 1.50 2.60E-03
APP CX601350 351 1.40 1.04E-02
CAT CD464332 847 1.39 6.36E-03
ENO1 CX603657 2023 1.39 7.60E-03
VAV1 BI961759 7409 1.37 2.70E-03
MYLK CX592941 4638 1.35 5.21E-02
EPO AB100030 2056 1.34 6.91E-03
IL15 AY682849 3600 1.34 4.57E-03
ITGAL CD464254 3683 1.32 1.32E-02
CD40 AY514017 958 1.30 4.73E-02
ACTN2 AB178951 88 1.29 1.76E-02
GDF8 AB033541 2660 1.29 4.87E-02
DAG1 CX600578 1605 1.28 1.20E-02
IGF2 U11241 3481 1.28 2.61E-02
HCK BM734694 3055 1.27 2.45E-02
ACAA2 CX603916 10449 1.25 1.67E-02Page 10 of 22
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COMT AB178284 1312 1.23 4.70E-04
FLII CX604876 2314 1.21 2.73E-02
ATP5a1 DN509143 498 1.21 5.18E-02
MYL9 CX594102 10398 1.18 1.56E-02
CCL13 ECA251188 6357 1.17 1.04E-02
GJA5 AY008788 2702 1.07 5.07E-02
ATP5C1 CX593263 509 0.90 4.87E-02
PYGL CX597788 5836 0.90 2.66E-02
FGR CD470584 2268 0.88 4.71E-02
MRPL49 CD469126 740 0.87 5.00E-02
GOT2 CX602317 2806 0.87 4.82E-02
ALOX5AP CD536322 241 0.86 1.95E-02
IMMT CX597479 10889 0.85 4.56E-02
ECHS1 CX604357 1892 0.85 4.05E-03
SLC2A1 DQ139875 6513 0.85 6.96E-03
CYTB X79547 4519 0.85 1.98E-02
EDN1 AY730629 1906 0.84 4.03E-02
PNMT AB071422 5409 0.84 2.08E-03
IL7 CX592622 3574 0.84 4.32E-02
IDH2 CX604713 3418 0.83 1.09E-02
PTGER4 DN505656 5734 0.83 1.72E-05
IL6ST DN507511 3572 0.83 4.34E-04
SCN4A ECU25990 6329 0.82 3.11E-02
CEBPB CX605423 1051 0.82 8.99E-03
SHMT2 CX605845 6472 0.82 2.08E-03
GLS CX600244 2744 0.81 7.01E-03
CYP19A1 ECA012610 1588 0.81 3.23E-02
PLAU CD471288 5328 0.81 3.89E-03
SLC25a5 DN506810 292 0.81 5.66E-03
ATP5o DN509617 539 0.80 1.98E-02
NQO1 DN508254 1728 0.80 2.44E-04
FYN CD528430 2534 0.78 1.17E-02
SLC8A1 DQ178640 6546 0.78 1.98E-03
Table 3: List of significant modulated genes (p < 0.05) expressed in the muscles suffering from PSSM. (Continued)(page number not for citation purposes)
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HNRPK CX598401 3190 0.77 4.69E-05
Leu-ARNt_TRNL1 X79547 4567 0.77 1.58E-03
MIF CX599697 4282 0.77 1.05E-02
ND2 X79547 4536 0.76 3.34E-03
CYTB X79547 4519 0.76 7.85E-03
OPRM1 ECA519535 4988 0.76 1.07E-04
CSF1 CD469550 1435 0.75 7.13E-04
RELB CD472197 5971 0.75 5.86E-05
Met-ARNt_TRNM X79547 4569 0.74 3.31E-03
SSPN CX605718 8082 0.72 1.65E-02
COX 3 X79547 4514 0.72 5.08E-03
CPT2 CX599757 1376 0.72 1.49E-04
PDE4B CD470720 5142 0.72 4.70E-06
ATP5e DN509652 514 0.72 1.22E-02
NR3C1 CX597756 2908 0.72 1.89E-02
STAT6 CD467276 6778 0.72 1.91E-02
ND2 X79547 4536 0.72 1.09E-04
COX 3 X79547 4514 0.70 2.46E-03
ND6 X79547 4541 0.70 4.69E-05
OXTR BM734870 5021 0.69 9.30E-04
ATP1B1 DN511201 481 0.69 2.20E-04
ATP5j DN507306 522 0.69 4.03E-02
PLG BM780461 5340 0.69 3.21E-04
COX 2 X79547 4513 0.69 1.03E-02
PKM2 CX604027 5315 0.69 1.82E-02
ATP5h CX599509 10476 0.69 1.20E-03
ATP5d CX603287 513 0.69 4.65E-04
CSF3 AF503365 1440 0.68 1.84E-05
Phe-ARNt_TRNF X79547 4558 0.67 4.07E-05
Glu-ARNt_TRNE X79547 4556 0.67 2.98E-06
TNFRSF4 CD465063 7293 0.66 6.88E-04
IGHE ECA305046 3497 0.66 4.10E-05
ATP5l CX603854 10632 0.66 4.69E-03
Table 3: List of significant modulated genes (p < 0.05) expressed in the muscles suffering from PSSM. (Continued)(page number not for citation purposes)
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Lys-ARNt_TRNK X79547 4566 0.65 1.60E-03
ND3 X79547 4537 0.64 1.12E-03
ND6 X79547 4541 0.63 7.60E-05
ATP2A1 AF489278 487 0.62 5.98E-04
TNFSF13B CD470712 10673 0.62 1.95E-05
Gly-ARNt_TRNG X79547 4563 0.62 4.97E-03
NFKBIB CX601294 4793 0.59 9.31E-06
PLCG2 CX603458 5336 0.58 7.89E-08
ND5 X79547 4540 0.57 1.01E-05
ND3 X79547 4537 0.57 1.65E-05
SLC25a17 CX598253 10478 0.57 2.13E-06
SRI DN506802 6717 0.57 4.60E-06
Val-ARNt_TRNV X79547 4577 0.56 1.95E-04
Asp-ARNt_TRND X79547 4555 0.55 1.76E-05
ND5 X79547 4540 0.54 1.39E-05
PDE4D CX593241 5144 0.54 1.26E-06
Ser-ARNt_TRNS2 X79547 4575 0.50 6.05E-03
Ile-ARNt_TRNI X79547 4565 0.49 1.21E-03
SLC25a15 CX598538 10166 0.48 4.95E-02
Leu-ARNt_TRNL2 X79547 4568 0.44 1.13E-05
Trp-ARNt_TRNW X79547 4578 0.40 2.13E-06
Thr-ARNt_TRNT X79547 4576 0.40 5.63E-05
Pro-ARNt_TRNP X79547 4571 0.39 2.59E-06
VEGF AB053350 7422 0.37 1.32E-06
PRKCA CX602892 5578 0.37 2.18E-06
SLC2A2 AJ715983 6514 0.35 2.18E-06
Ala-ARNt_TRNA X79547 4553 0.35 1.10E-04
Tyr-ARNt_TRNY X79547 4579 0.35 1.04E-03
Asn-ARNt_TRNN X79547 4570 0.33 8.13E-06
Cys-ARNt_TRNC X79547 4511 0.28 4.48E-06
Gln-ARNt_TRNQ X79547 4572 0.21 3.81E-07
Significant p-value (p < 0.05) indicated that the expression ratio was significantly different from 1.
P-values are expressed in scientific format: 1E-3 means 1.10-3.
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same methods as previously described [24,31].
The muscle biopsies mainly collected muscle fiber cells
and also some leucocytes that were in the muscular blood
vessels and in the muscle connective tissue itself because
of chronic inflammation observed in PSSM muscles. His-
tological data showed mild or severe inflammation with
macrophages and lymphocyte infiltration. These leuco-
cytes should have an important signaling activity which
was observed in the present results. However, the relative
amount of muscle RNA extracted from the muscle was
Table 4: Real time quantitative RT-PCR Results of the top ten up- and down-regulated genes measured by the microarray analysis.
Gene Normalized ratio of microarray 
analysis
Relative expression ratio of quantitative 
RT-PCR
RT-PCR ratio different from 
1 p-value
UP
IL18 6.20 4.29 0.01
CTSS 3.17 1.61 0.05
LUM 3.15 1.75 0.05
CD44 2.42 2.87 0.01
FN1 2.17 0.72 0.05
GSTO1 2.03 3.23 0.01
VCAM1 1.98 7.21 0.01
ITGB1 1.87 0.09 0.05
CXCR4 1.81 3.43 0.01
HIF1A 1.73 2.99 0.01
DOWN
NFKBIB 0.59 0.60 0.05
PLCG2 0.58 0.97 NS
ND3 0.57 0.60 0.05
SLC25a17 0.57 1.77 0.05
SRI 0.57 0.98 NS
ND5 0.54 0.49 0.05
PDE4D 0.54 0.67 0.05
SLC25a15 0.48 0.96 NS
VEGF 0.37 0.35 0.05
PRKCA 0.37 0.16 0.05
SLC2A2 0.35 0.79 0.05
One sample T-test compared the relative expression ratio of RT-PCR results against 1. For p > 0.05,
P-values were non-significant (NS).Page 14 of 22
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Categories of cellular gene functionsFigure 3
Categories of cellular gene functions. Our list of modulated genes was classified by categories of cellular functions using a 
data mining software (Ingenuity Pathway Analysis®). The analysis identified the biological functions that were the most signifi-
cant to the gene list results. The significant genes associated with biological functions in the knowledge database (gene func-
tions described in published papers) were considered for the analysis. The Fischer exact test was used to calculate a p-value 
determining the probability that each biological function assigned to that data set is due to chance alone. In the present figure, 
protein synthesis, apoptosis, cellular movement, growth and proliferation are the main significant cellular functions (p < 0.05) 
that are associated to the modulated genes.
BMC Veterinary Research 2009, 5:29 http://www.biomedcentral.com/1746-6148/5/29more than 98% of the total RNA according to the relative
mass of tissue. In addition, very little blood was collected
with the automatic biopsy needle and the blood at the
surface of the sample was absorbed before freezing the
biopsy into nitrogen.
The gene expression analysis of the PSSM muscles mainly
revealed the metabolic disorders due to this equine gly-
cogenosis but not directly the genes suspected to be
responsible for this pathology. The candidates GBE1,
PFKM, AGL and even GYS1 were not significantly modu-
lated. GYS1 with a G-to-A mutation has been identified to
be associated with PSSM in different breeds [21]. Most of
the PSSM cases (77) diagnosed by histology were hetero-
zygous for the mutation but 22 PSSM cases were of the
homozygous wild type and the GYS1 mutation alone
could not explain the glycogenosis. It has been suggested
that another non-GYS1 glycogenosis could explain these
22 PSSM cases. The glycogen synthase activity measured
in vitro was higher in PSSM muscle. In the present study,
all the PSSM horses were mutated for GYS1. The
homozygous horses exhibited more severe histological
disorders with characteristic amylase-resistant aggregates
but also tissular damages, namely fiber necrosis, anisocy-
tosis, some endomysial fibrosis and fatty infiltration.
The main dysfunctions observed were a chronic inflam-
matory myopathy and a severe hypoxia associated with a
very low activity of the oxidative energetic metabolism.
The chronic inflammation of the PSSM muscle was
revealed both by histological observations and the
number of up-regulated genes involved in inflammation
Relationships between pairs of genes and cellular compartmentsFigure 4
Relationships between pairs of genes and cellular compartments. The analysis of the main metabolic pathways and 
their dysfunctions was performed using a data mining software (Predictsearch®). Briefly, gene aliases corresponding to the sig-
nificant modulated genes were submitted as queries to PubMed in order to collect titles and abstracts of all related publica-
tions. The results showed that a part of the significant modulated genes were strongly associated with the following terms: 
skeletal muscle, mitochondria, myoblast, endoplasmic reticulum.Page 16 of 22
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ITGB2, VCAM, CXCR4, LTF, GSTO1 and LUM. These
genes could be expressed in the leukocytes present in the
PSSM muscle and/or in muscle fibers. Interleukin 18
(IL18) was the most up-regulated gene and four other
genes had the highest expression ratios: CTSS, LUM,
CD44 and FN1. The chemokine receptor 4 (CXCR4) has
been observed more specifically in some idiopathic
inflammatory myopathies in humans [34]. This gene
encodes a CXC chemokine receptor specific for stromal
cell-derived factor-1. This protein has 7 transmembrane
regions and is located on the cell surface.
According to the histological data, it was postulated that
this inflammatory context was stimulated by muscle fiber
necrosis and progressed to fiber regeneration and
endomysial fibrosis. This mecanism is illustrated by (i)
the insulin like growth hormone type II (IGF2) that was
also up-regulated and contributed to myoblast differenti-
ation [35] and mitochondrial biogenesis [36]; (ii) the up-
regulation of lumican (LUM) gene that encodes for a
small keratan sulfate proteoglycan molecule, which is
involved in the collagen fibrillogenesis and fibrous tissue
formation.
IL18 is an interferon gamma-induced protein that is
involved in immune cell activation, proliferation, infiltra-
tion, apoptosis and cytotoxicity. In humans, the plasmatic
concentration of IL18 is an interesting predictor of the risk
of myocardial infarction, artherosclerosis and metabolic
syndrome observed in obesity [37,38]. A high plasmatic
concentration of IL18 is correlated with insulin resistance
and body mass index. In PSSM horses, an increased sensi-
tivity to insulin has also been observed [14]. The measure
of IL18 concentration could be an interesting blood
marker of PSSM. As indicated by the data mining analysis,
the chronic inflammation and IL18 up-regulation could
be responsible of PI3K/Akt/GSK3β activation [39]. The
up-regulation GSK3β under its active form could be
responsible for the glycogen synthase (GYS1) inhibition
as indicated by data mining analysis. The down-regula-
tion of the glycogen metabolism was also indicated by a
low expression value of PYGL. The up-regulation of active
GSK3β could be responsible of hypoxia and low capillar-
ization of the PSSM muscle. The GSK3β activity increases
the HIF1α destabilization by phosphorylation which is
finally degraded in the proteasome [39,40]. Conse-
quently, the low expression of HIF1α should down-regu-
late VEGFα expression [41] which contributes to a poor
capillarization and increased chronic hypoxia of the
regenerated muscle fibers. The down-regulated protein
kinase Cα (PRKCα) gene is involved in many important
signaling pathways like calcium, MAPK and VEGFα.
Relationships between metabolic pathways or disorders and genesFigure 5
Relationships between metabolic pathways or disorders and genes. The analysis of the main metabolic pathways and 
their dysfunctions was performed using a data mining software (Predictsearch®). Briefly, gene aliases corresponding to the sig-
nificant modulated genes were submitted as queries to PubMed in order to collect titles and abstracts of all related publica-
tions. The PubMed ID of the related publications were indicated on the figures 6, 7 and 8. The results showed that the more 
frequent biological activities cited in relationship with the set of genes were glycolysis, respiratory chain, hypoxia, glycogen syn-
thase and inflammatory myopathy.Page 17 of 22
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down-regulated IL6ST, IL7. It was interesting to observe
the up-regulation of the erythropoietin cytokine gene
(EPO), which also demonstrated hypoxia in the PSSM
muscle. This EPO transcript could be expressed both in
blood and muscle cells. This plasmatic cytokine is well
known to regulate red cell production by promoting
erythroid differentiation and initiating hemoglobin syn-
thesis. This cytokine also has neuroprotective activity and
an anti-apoptotic neuronal effect useful for treatment of a
variety of potential brain injuries [42,43]. The use of EPO
in chronic kidney disease [44], heart failure and other car-
diovascular diseases [45] demonstrated the pleiotropic
cytokine activity of EPO as anti-apoptotic and with a tis-
sue protective effect against hypoxia. Erythropoietin injec-
tion could be useful for the treatment of hypoxia in PSSM
cases.
Hypoxia could also be related to the severe oxidative
metabolism dysfunction observed at the mitochondrial
level. Ultrastructural observations showed a decrease in
the number of mitochondria and mitochondrial damages
Mitochondrial dysfunctionsFigure 6
Mitochondrial dysfunctions. Mitochondria is one of the compartment detected by electronic microscopy and data mining 
as illustrated in figure 4. In the mitochondria, the tRNA were severely down regulated (fold change between -4.83 and -2.27). 
The other mitochondrial genes ND2, ND3, ND5, ND6, COX2 and COX3 were moderately down-regulated but with low 
expression values (fold changes between -1.31 and -1.85). Other nuclear genes involved in the aerobic metabolism of the mito-
chondria were down regulated as well: UCP2, GNAS, SLC25a15, SLC2a2 (GLUT2), ATP5L, ATP5J, ATP5D and ATP5H. The 
PubMed ID of the related publications found by the data mining analysis were indicated on the figure (8611159; 7533543; 
2988521).Page 18 of 22
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tion of myelinic bodies. The genomic markers of the mito-
chondrial dysfunction were the low level of most of the
tRNA and the down-regulated genes coding for the respi-
ratory chain sub-units (ND2, ND3, ND5, ND6, COX2 and
COX3). The respiratory chain dysfunction in conjunction
with a low expression of UCP2 could increase the reactive
oxygen species accumulation in the mitochondria and
could be responsible for muscle fiber apoptosis and
necrosis. In addition, other nuclear genes involved in the
mitochondrial oxidative metabolism were down-regu-
lated (GNAS, SLC25A15, SLC2a2 (GLUT2), ATP5L,
ATP5J, ATP5D and ATP5H). The down-regulation of the
glucose transporter GLUT2 could also be related to the
hypoxia. This transporter facilitates bidirectional trans-
port of glucose through the cellular membrane and
decreases the glucose available for glycogen synthesis, gly-
colysis and the Krebs cycle. The mitochondrial carrier
ornithine transporter (SLC25A15) down-regulation also
indicates a reduction of mitochondrial activity.
Conclusion
Protein synthesis, apoptosis, cellular movement, growth
and proliferation were the main cellular functions associ-
ated with the modulated genes. This was in agreement
with the histological observations of active muscle fiber
regeneration in PSSM muscles. Several up-regulated
genes, especially interleukine 18 (IL18), revealed a severe
muscular inflammation in PSSM muscles as confirmed by
histological findings of leucocyte infiltrations. The up-reg-
ulation of active glycogen synthase kinase-3 (GSK3β)
could be responsible for both glycogen synthase (GYS1)
Inflammatory processFigure 7
Inflammatory process. The chronic inflammation of the PSSM muscle was revealed both by histological observations and 
the number of up-regulated genes involved in inflammation pathways as illustrated in data mining results figure 5: IL18, CD44, 
CD69, CTSS, FN1, HSPA5, ITGB1, ITGB2, VCAM, CXCR4, LTF, GSTO1 and LUM. These genes could be expressed in the leu-
kocytes present in the PSSM muscle and/or in muscle fibers. The PubMed ID of the related publications found by the data min-
ing analysis were indicated on the figure (15574430; 15661938; 12742663; 12101280; 15019705; 2988521; 11890723).Page 19 of 22
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lization. Many genes involved in mitochondrial functions
were down-regulated and utltrastructural observations
revealed many mitochondrial disorders. Consequently,
the main disorders observed in PSSM muscles could be
related to mitochondrial dysfunctions, glycogenesis inhi-
bition and the chronic hypoxia.
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